A company rarely gets heavy all at once. First the old win keeps getting a vote, the clean plan starts paying rent to yesterday's structure, or the best people work around the system to keep the day moving.
Use this snapshot to spot the pattern early: what still helps the company move, what slows the next move down, and where the pressure may show up before the market gives it a lazy name.
The Read
The habit under the headline.
First-Mover Under Pressure
Novo still owns deep obesity trust and has the first oral weight-loss GLP-1 with real traction. The pressure is that Lilly is turning patient convenience into a competitive weapon.
Scorecard + Read Checks
The number, then the pressure points.
GPI Score
6.60
State
Transitioning
Revenue
DKK 309.1B (2025)
| Decision Latency | 6 | Novo still has deep disease-area focus, but market-share pressure, a leadership reset, and restructuring make decisions heavier. |
| Error Correction | 8 | The company is correcting in public through leadership change, job cuts, pipeline resets, and a hard push behind oral Wegovy. |
| Knowledge Location | 6 | Semaglutide knowledge is deep and close to the work, though large-company structure still shapes how quickly learning travels. |
| Structural Lock-In | 6 | Novo is tied to its GLP-1 franchise, manufacturing base, and obesity-care identity, but still has room to redirect. |
| Talent Flow | 7 | Restructuring and layoffs can free capacity, but they also risk losing stored judgment during a market fight. |
| Capital Intensity | 7 | Oral and injectable GLP-1 scale requires heavy investment in manufacturing, trials, and market access. |
| Knowledge Velocity | 6 | Novo learns quickly inside obesity care, but the market is now moving faster than the old lead allowed. |
Numbers Worth Holding
The filing pile gets smaller here.
Still Working / Still Stuck
What still has legs. What still drags.
- Deep obesity-care trust
- Semaglutide knowledge base
- First oral Wegovy traction
- Global commercial reach
- Strong prescriber familiarity
- Market Share Loss
- Pricing Pressure
- Restructuring
- Layoffs as Adaptation
- Knowledge Drain
- Litigation Exposure
The Line
"Novo still has the first pill people are actually filling. The problem is that Lilly made the morning routine part of the fight."